• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

在一家主要癌症中心的肠杆菌科血流感染中，发现头孢他啶-阿维巴坦的非敏感性率较高，并鉴定出新型德里金属β-内酰胺酶的产生。

High Rates of Nonsusceptibility to Ceftazidime-avibactam and Identification of New Delhi Metallo-β-lactamase Production in Enterobacteriaceae Bloodstream Infections at a Major Cancer Center.

机构信息

Division of Pharmacy.

Department of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, Texas.

出版信息

Clin Infect Dis. 2016 Oct 1;63(7):954-958. doi: 10.1093/cid/ciw398. Epub 2016 Jun 16.

DOI:10.1093/cid/ciw398
PMID:27313265
Abstract

Resistance to the novel β-lactam/β-lactamase inhibitor combination ceftazidime-avibactam (CAZ-AVI) among carbapenem-resistant Enterobacteriaceae (CRE) has infrequently been reported in the United States. We report unexpectedly high rates of resistance to CAZ-AVI in CRE bloodstream isolates at our institution associated with the nonoutbreak spread of New Delhi metallo-β-lactamase in diverse Enterobacteriaceae species.

摘要

耐新型β-内酰胺/β-内酰胺酶抑制剂组合头孢他啶-阿维巴坦（CAZ-AVI）的碳青霉烯类耐药肠杆菌科（CRE）在美国的报道很少见。我们报告了在我们机构中 CRE 血流分离株对 CAZ-AVI 的耐药率出人意料地高，这与新德里金属β-内酰胺酶在不同肠杆菌科物种中的非暴发传播有关。

相似文献

1
High Rates of Nonsusceptibility to Ceftazidime-avibactam and Identification of New Delhi Metallo-β-lactamase Production in Enterobacteriaceae Bloodstream Infections at a Major Cancer Center.在一家主要癌症中心的肠杆菌科血流感染中，发现头孢他啶-阿维巴坦的非敏感性率较高，并鉴定出新型德里金属β-内酰胺酶的产生。
Clin Infect Dis. 2016 Oct 1;63(7):954-958. doi: 10.1093/cid/ciw398. Epub 2016 Jun 16.
2
Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae?头孢他啶-阿维巴坦和氨曲南能否克服肠杆菌科细菌中金属β-内酰胺酶介导的β-内酰胺耐药性？
Antimicrob Agents Chemother. 2017 Mar 24;61(4). doi: 10.1128/AAC.02243-16. Print 2017 Apr.
3
Treating complicated carbapenem-resistant enterobacteriaceae infections with ceftazidime/avibactam: a retrospective study with molecular strain characterisation.使用头孢他啶/阿维巴坦治疗复杂碳青霉烯类耐药肠杆菌科感染：一项结合分子菌株特征的回顾性研究。
Int J Antimicrob Agents. 2017 Jun;49(6):770-773. doi: 10.1016/j.ijantimicag.2017.01.018. Epub 2017 Apr 4.
4
Activity of Ceftazidime-Avibactam and Aztreonam-Avibactam against OXA-48-Carrying Enterobacteriaceae Isolated as Part of the International Network for Optimal Resistance Monitoring (INFORM) Global Surveillance Program from 2012 to 2015.2012 年至 2015 年期间，作为国际最佳耐药监测网络（INFORM）全球监测项目的一部分，分离出携带 OXA-48 酶的肠杆菌科细菌，对头孢他啶-阿维巴坦和氨曲南-阿维巴坦的活性进行评估。
Antimicrob Agents Chemother. 2018 Nov 26;62(12). doi: 10.1128/AAC.00592-18. Print 2018 Dec.
5
Activity of ceftazidime-avibactam against multidrug-resistance Enterobacteriaceae expressing combined mechanisms of resistance.头孢他啶-阿维巴坦对表达联合耐药机制的多重耐药肠杆菌科细菌的活性。
Enferm Infecc Microbiol Clin. 2017 Oct;35(8):499-504. doi: 10.1016/j.eimc.2016.09.013. Epub 2016 Nov 22.
6
Ceftazidime-avibactam in the treatment of bacteremia due to carbapenem-resistant gram-negative bacteria in hematological patients: Experience in a single center.头孢他啶-阿维巴坦治疗血液科患者碳青霉烯类耐药革兰阴性菌菌血症：单中心经验。
J Infect Chemother. 2024 Jul;30(7):608-615. doi: 10.1016/j.jiac.2024.01.007. Epub 2024 Jan 11.
7
Low Frequency of Ceftazidime-Avibactam Resistance among Enterobacteriaceae Isolates Carrying Collected in U.S. Hospitals from 2012 to 2015.2012年至2015年在美国医院收集的携带[相关因素未给出]的肠杆菌科分离株中头孢他啶-阿维巴坦耐药的低发生率
Antimicrob Agents Chemother. 2017 Feb 23;61(3). doi: 10.1128/AAC.02369-16. Print 2017 Mar.
8
Efficacy of ceftazidime-avibactam in the treatment of infections due to Carbapenem-resistant Enterobacteriaceae.头孢他啶-阿维巴坦治疗碳青霉烯类耐药肠杆菌科细菌感染的疗效。
BMC Infect Dis. 2019 Sep 4;19(1):772. doi: 10.1186/s12879-019-4409-1.
9
Ceftazidime-Avibactam as Salvage Therapy for Infections Caused by Carbapenem-Resistant Organisms.头孢他啶-阿维巴坦作为耐碳青霉烯类微生物所致感染的挽救治疗药物
Antimicrob Agents Chemother. 2017 Jan 24;61(2). doi: 10.1128/AAC.01964-16. Print 2017 Feb.
10
Ceftazidime-Avibactam as Salvage Therapy for Infections Caused by Coresistant to Carbapenems and Polymyxins.头孢他啶-阿维巴坦作为治疗对碳青霉烯类和多黏菌素类耐药的感染的补救疗法。
Antimicrob Agents Chemother. 2019 Sep 23;63(10). doi: 10.1128/AAC.00528-19. Print 2019 Oct.

引用本文的文献

1
Phenotypic Ultra-Rapid Antimicrobial Susceptibility Testing for Ceftazidime-Avibactam: In Support of Antimicrobial Stewardship.头孢他啶-阿维巴坦的表型超快速抗菌药物敏感性试验：支持抗菌药物管理
Microorganisms. 2025 Feb 13;13(2):414. doi: 10.3390/microorganisms13020414.
2
Laboratory detection of carbapenemases among Gram-negative organisms.革兰氏阴性菌中碳青霉烯酶的实验室检测
Clin Microbiol Rev. 2024 Dec 10;37(4):e0005422. doi: 10.1128/cmr.00054-22. Epub 2024 Nov 15.
3
A Case of New Delhi Metallo-ß-Lactamase-Producing Enterobacter and a Review of Cases in the United States From January 2009 to September 2022.
一例产新德里金属β-内酰胺酶的肠杆菌病例及2009年1月至2022年9月美国病例回顾
Cureus. 2024 May 13;16(5):e60200. doi: 10.7759/cureus.60200. eCollection 2024 May.
4
In vitro mimicry of in vivo KPC mutations by ceftazidime-avibactam: phenotypes, mechanisms, genetic structure and kinetics of enzymatic hydrolysis.头孢他啶-阿维巴坦体外模拟体内 KPC 突变：表型、机制、酶水解的遗传结构和动力学。
Emerg Microbes Infect. 2024 Dec;13(1):2356146. doi: 10.1080/22221751.2024.2356146. Epub 2024 Jun 4.
5
Successful Treatment of Carbapenem-Resistant Acinetobacter baumannii Meningitis With Sulbactam-Durlobactam.舒巴坦-多利培南成功治疗耐碳青霉烯鲍曼不动杆菌脑膜炎
Clin Infect Dis. 2024 Oct 15;79(4):819-825. doi: 10.1093/cid/ciae210.
6
Clinical distribution of carbapenem genotypes and resistance to ceftazidime-avibactam in Enterobacteriaceae bacteria.肠杆菌科细菌中产碳青霉烯酶基因型的临床分布及对头孢他啶-阿维巴坦的耐药性。
Front Cell Infect Microbiol. 2024 Mar 20;14:1345935. doi: 10.3389/fcimb.2024.1345935. eCollection 2024.
7
Structural insights into the molecular mechanism of high-level ceftazidime-avibactam resistance conferred by CMY-185.CMY-185 介导的高产头孢他啶-阿维巴坦耐药性的分子机制的结构见解。
mBio. 2024 Feb 14;15(2):e0287423. doi: 10.1128/mbio.02874-23. Epub 2024 Jan 5.
8
Ceftazidime-avibactam use for the treatment of OXA-48- and/or New Delhi metallo-β-lactamase-producing in cancer patients: a retrospective observational study.头孢他啶-阿维巴坦治疗癌症患者中产 OXA-48-和/或新德里金属β-内酰胺酶的应用：一项回顾性观察研究。
Ann Saudi Med. 2023 Nov-Dec;43(6):373-379. doi: 10.5144/0256-4947.2023.373. Epub 2023 Dec 7.
9
Global impact of antibacterial resistance in patients with hematologic malignancies and hematopoietic cell transplant recipients.血液恶性肿瘤和造血细胞移植受者的抗菌耐药全球影响。
Transpl Infect Dis. 2023 Nov;25 Suppl 1(Suppl 1):e14169. doi: 10.1111/tid.14169. Epub 2023 Oct 20.
10
#AMRrounds: a systematic educational approach for navigating bench to bedside antimicrobial resistance.#抗菌药物耐药性巡诊：一种从实验室到临床应对抗菌药物耐药性的系统性教育方法
JAC Antimicrob Resist. 2023 Aug 14;5(4):dlad097. doi: 10.1093/jacamr/dlad097. eCollection 2023 Aug.